1. Home
  2. QLYS vs BLLN Comparison

QLYS vs BLLN Comparison

Compare QLYS & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$90.38

Market Cap

3.4B

Sector

Technology

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$70.65

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QLYS
BLLN
Founded
1999
2016
Country
United States
United States
Employees
N/A
713
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.5B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
QLYS
BLLN
Price
$90.38
$70.65
Analyst Decision
Hold
Buy
Analyst Count
12
7
Target Price
$136.00
$129.57
AVG Volume (30 Days)
538.1K
297.5K
Earning Date
05-05-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
16.99
N/A
EPS
5.44
N/A
Revenue
$321,607,000.00
N/A
Revenue This Year
$9.96
$45.89
Revenue Next Year
$7.15
$30.17
P/E Ratio
$16.52
N/A
Revenue Growth
15.32
N/A
52 Week Low
$85.14
$61.96
52 Week High
$155.47
$138.70

Technical Indicators

Market Signals
Indicator
QLYS
BLLN
Relative Strength Index (RSI) 33.69 44.27
Support Level $85.14 $63.98
Resistance Level $102.25 $100.28
Average True Range (ATR) 3.90 4.73
MACD 0.39 0.89
Stochastic Oscillator 10.71 47.83

Price Performance

Historical Comparison
QLYS
BLLN

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: